

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2023

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 8 August 2023 (the “**Announcement**”) in relation to the preliminary financial data for the six months ended 30 June 2023 (the “**Reporting Period**”) of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the six months ended 30 June 2023 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

Unit: Ten thousand Yuan
Currency: RMB

| | The Reporting Period | Same period of last year | Increase/Decrease (%) |
|--|---|---|------------------------------------|
| Revenue | 3,838,753.15 | 3,612,891.00 | 6.25 |
| Operating profit | 129,511.32 | 103,239.09 | 25.45 |
| Total profit | 129,165.43 | 103,455.54 | 24.85 |
| Net profit attributable to shareholders of the listed company | 83,025.11 | 67,421.59 | 23.14 |
| Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses | 79,464.63 | 65,285.73 | 21.72 |
| Basic earnings per share (Yuan) | 1.49 | 1.21 | 23.14 |
| Weighted average ROE | 5.04% | 4.44% | Increased by 0.60 percentage point |
| | At the end of the Reporting Period | At the beginning of the Reporting Period | Increase/Decrease (%) |
| Total assets | 4,988,293.88 | 4,261,576.06 | 17.05 |
| Equity attributable to shareholders of listed company | 1,661,353.22 | 1,612,589.04 | 3.02 |
| Share capital(in 0'000 shares) | 55,656.51 | 42,812.70 | 30.00 |
| Net assets per share attributable to shareholders of listed company (Yuan) | 29.85 | 28.97 | 3.04 |

Notes:

1. The financial data as at the end of the Reporting Period are filled in according to the consolidated financial statements of Sinopharm Accord.
2. On 11 May 2023, the 2022 annual general meeting of Sinopharm Accord approved the “Proposal on Profit Distribution for the Year 2022 and Capitalization of Capital Reserve of Sinopharm Accord” (《國藥一致 2022 年度利潤分配及資本公積金轉增股本預案》), which agreed on the issuance of shares of Sinopharm Accord on the basis of 3 new shares for every 10 shares to all shareholders by way of capitalization of capital reserve, resulting in a total of 128,438,094 shares converted and issued. The equity distribution plan for A shares and B shares was completed on 1 June 2023 and 5 June 2023, respectively. In accordance with the relevant requirements of the Compilation Rules for Information Disclosure by Companies Offering Securities to the Public No. 9 – Computation and Disclosure of Return on Net Assets and Earnings per Share (《公開發行證券的公司信息披露編報規則第 9 號—淨資產收益率和每股收益的計算及披露》), Sinopharm Accord has recalculated the earnings per share for the comparative period on the basis of the total number of shares following the capitalization issue of shares, and also recalculated net assets per share attributable to shareholders of listed

company. The basic earnings per share over the same period of last year and the net assets per share attributable to shareholders of listed company at the end of last year were adjusted from RMB1.57 and RMB37.67 respectively to RMB1.21 and RMB28.97.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

In the first half of 2023, Sinopharm Accord has focused on the works of high-quality development and has achieved steady growth in operating scale and efficiency by adjusting and optimizing its business structure, promoting business transformation and enhancing the effectiveness of its management and control. According to the preliminary accounting records, during the Reporting Period, Sinopharm Accord has achieved a revenue of RMB38.388 billion, representing a year-on-year increase of 6.25%; an operating profit of RMB1.295 billion, representing a year-on-year increase of 25.45%; a total profit of RMB1.292 billion, representing a year-on-year increase of 24.85%; a net profit of RMB1.029 billion, representing a year-on-year increase of 29.52%; and a net profit attributable to shareholders of the listed company of RMB830 million, representing a year-on-year increase of 23.14%. As a result, the basic earnings per share increased by 23.14%, and the weighted average ROE increased by 0.60 percentage point.

The distribution segment achieved a revenue of RMB26.520 billion, representing an increase of 4.17% year on year, and a net profit of RMB531 million, representing an increase of 0.36% year on year. The retail segment achieved a revenue of RMB12.350 billion, representing an increase of 10.77% year on year, and a net profit of RMB302 million, representing an increase of 113.70% year on year.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC

8 August 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*